Compare FLWS & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLWS | IMRX |
|---|---|---|
| Founded | 1976 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 196.7M | 232.9M |
| IPO Year | 1999 | 2021 |
| Metric | FLWS | IMRX |
|---|---|---|
| Price | $4.39 | $6.20 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $7.50 | ★ $17.20 |
| AVG Volume (30 Days) | ★ 1.0M | 956.2K |
| Earning Date | 01-29-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,658,768,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.93 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.93 | $1.10 |
| 52 Week High | $9.17 | $10.08 |
| Indicator | FLWS | IMRX |
|---|---|---|
| Relative Strength Index (RSI) | 61.35 | 40.72 |
| Support Level | $3.43 | $5.93 |
| Resistance Level | $5.18 | $6.73 |
| Average True Range (ATR) | 0.33 | 0.41 |
| MACD | 0.19 | -0.14 |
| Stochastic Oscillator | 63.45 | 14.75 |
1-800-Flowers.com Inc is a provider of gifts designed to help customers express, connect, and celebrate. The company's e-commerce business platform features all brands, including 1-800-Flowers.com, 1-800-Baskets.com, Cheryl's Cookies, Harry and David, PersonalizationMall.com, Shari's Berries, FruitBouquets.com, Moose Munch, The Popcorn Factory, Wolferman's Bakery, Stock Yards, and Simply Chocolate. The company's business segments are; Consumer Floral and Gifts, BloomNet, and Gourmet Foods & Gift Baskets. The maximum revenue for the company is generated from its Gourmet Foods & Gift Baskets segment.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.